Heron Therapeutics reported Q2 2026 net revenue of $37.7 million and ended the quarter with $42.7 million in cash. The company amended its credit facility with Hercules Capital, reducing outstanding principal by $13.5 million immediately and potentially another $4 million by September 15, 2026. Heron withdrew its full-year 2026 financial guidance due to a Delaware court patent decision affecting CINVANTI sales forecasts and paused planned sales force expansion. Management stated the company is considering strategic alternatives while tightening spending. Heron Therapeutics operates in the biotechnology industry, developing and commercializing therapeutic innovations for acute care and oncology patients.
